State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 4,994,047 shares of CRISPR Therapeutics AG common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported 4,994,047 shares of CRISPR Therapeutics AG common stock.
  • Percent of class: The reported holdings represent 5.2% of the outstanding class of common stock.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote for 4,737,614 shares, with zero sole voting power.
  • Shared dispositive power: The filing reported shared power to dispose of 4,994,047 shares, with zero sole dispositive power.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Filing subsidiaries: Five subsidiaries - SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. - are identified as the investment adviser entities through which the position is held.

State Street's Schedule 13G Filing on CRISPR Therapeutics Holdings

State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing a 5.2% beneficial ownership position in CRISPR Therapeutics AG (CUSIP: H17182108), whose principal executive offices are located at Baarerstr. 14, Zug, Switzerland, 6300. According to the filing, the event triggering the disclosure occurred on September 30, 2026, and the statement was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026.

The filing reports that State Street holds an aggregate of 4,994,047 shares on a beneficial basis. All voting power is shared rather than sole: the company disclosed shared voting power over 4,737,614 shares and shared dispositive power over the full 4,994,047 shares, with sole voting and sole dispositive power each reported as zero. The filing identifies State Street as a parent holding company (type "HC"), with the holdings attributed to five subsidiary investment adviser entities listed under Item 7.

In the certification included with the filing, State Street stated that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." The filing notes the disclosure is not applicable to items addressing ownership of 5% or less, group membership, or group dissolution.

What Was Disclosed

State Street Corporation disclosed a 5.2% beneficial ownership stake of 4,994,047 shares of CRISPR Therapeutics AG common stock via a Schedule 13G, with shared voting power over 4,737,614 shares, as of September 30, 2026.